Back to journals
Academic Journal

Biorxiv

53 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 53 psychedelic papers Blossom tracks from Biorxiv line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of August 2026; its full catalogue is much larger.

How much psychedelic research does Biorxiv carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

10papers published in 2023

+43% vs 2022

26 published by 2023

Browse papers→

Don't read as the journal's total output: only the 53 of 53 tracked psychedelic papers from Biorxiv with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Biorxiv publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Neuroimaging & Brain Measures
19
Depressive Disorders
14
Anxiety Disorders
8
Schizophrenia
6
Chronic Pain
5
Addiction & Substance Use
4
Microdosing
4
PTSD
4
Other
13

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Biorxiv cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
25
LSD
22
Ketamine
10
DMT
7
5-MeO-DMT
5
MDMA
5
Ayahuasca
3
2C-X
1
Other
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Biorxiv has 53 tracked papers indexed in Blossom (2017–2026) from 374 authors, most often covering Psilocybin, LSD and Ketamine, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.

Published Papers

Open Accessindividual

Psilocybin acutely dissociates cognitive and affective empathy, with empathic concern predicting persisting positive psychological effects

This secondary analysis of an RCT (n=60) in healthy volunteers, psilocybin temporarily changed different aspects of empathy in opposite directions. Participants became less accurate at identifying positive emotions in others, while showing greater emotional responses to positive emotions and greater empathic concern for others. These changes were no longer present one week later, although greater empathic concern during the experience was associated with more positive changes in mood, relationships, and attitudes toward life and self at follow-up.

Published
Journal
Biorxiv
Authors
Mason, N., Mallaroni, P., Kuypers, K., De La Torre Fornell, R., Reckweg, J., Preller, K., Ramaekers, J.
Open Accessindividual

Estimating Cardiac 5-HT2B Safety Margins for Repeated Low-Dose Psilocybin Using an Exposure-Response Model

This modelling study, supported by a rat experiment, assessed whether repeated low-dose psilocybin could pose a heart valve risk by acting on the 5-HT2B receptor. It found a 3 mg daily regimen had a large safety margin in the model, and rats exposed to higher psilocin levels for 12 days showed no valve damage, though slow fibrosis could not be ruled out.

Published
Journal
Biorxiv
Authors
Tyler, W. J., Sellers, E., McDonnell, M. B.
Open Accessindividual

Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors

This mouse study examined how psilocybin affects dendrites in the medial frontal cortex and found that it briefly increased calcium activity in apical dendritic tufts only during quiet wakefulness. The effect depended on 5-HT2A receptors, and psilocybin disrupted the usual link between dendritic activity and later spine formation.

Published
Journal
Biorxiv
Authors
Savalia, N. K., Shao, L. X., Knox, C. A., Gilbert, A. D., Jiang, Q., Kwan, A. C.
Open Accessmeta

Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female Participants

This pooled analysis (n=72; 31 male, 41 female) of two double-blind, placebo-controlled studies comparing psilocybin (15 mg), 2C-B (20 mg), and LSD (50 μg) in healthy volunteers found that female participants reported more intense acute subjective effects and greater perceived impairment than male participants across all three drugs, with no sex differences in empathy or peak drug concentrations, pointing to pharmacodynamic rather than pharmacokinetic causes.

Published
Journal
Biorxiv
Authors
Mason, N. L., Haijen-Bongers, E. C., Kuypers, K. P., Frick, A., Toennes, S. W., Mallaroni, P., Ramaekers, J. G.
Open Accessindividual

Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram

This brain imaging study examined resting-state fMRI from people with major depressive disorder before and after treatment with psilocybin or escitalopram, using computer models to test how the brain responded to artificial perturbations. It found that psilocybin increased brain reconfiguration under perturbation, while escitalopram decreased it, suggesting different effects on brain flexibility and stability.

Published
Journal
Biorxiv
Authors
Dagnino, P. C., Acero-Pousa, I., Carhart-Harris, R., Erritzoe, D., Nutt, D. J., Kringelbach, M. L., Sanz Perl, Y., Deco, G.
Open Accessindividual

Single-nucleus transcriptomics reveals cell type-specific and time-dependent effects of psilocybin and ketamine on gene expression

This mouse study used single-nucleus RNA sequencing to examine how psilocybin and ketamine change gene expression in the medial frontal cortex over time. It found cell type-specific effects, with psilocybin altering genes linked to synaptic plasticity, metabolism and glial function, and its transcriptional response peaking earlier and later than ketamine’s.

Published
Journal
Biorxiv
Authors
Liao, C., O’Farrell, E., Weiner, A. M., Qalieh, Y., Savalia, N. K., Girgenti, M. J., Kwan, K. Y., Kwan, A. C.

Quick Facts

Papers Indexed
53
Publisher
openRxiv
Website
Visit